You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 24, 2024

Claims for Patent: 7,521,425

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,521,425

Title:	Anti-angiogenic compounds
Abstract:	The present invention provides AA targeting compounds which comprise AA targeting agent-linker conjugates which are linked to a combining site of an antibody. Various uses of the compounds are provided, including methods to treat disorders connected to abnormal angiogenesis.
Inventor(s):	Bradshaw; Curt W. (San Diego, CA), Doppalapudi; Venkata Ramana (San Diego, CA), Lai; Jing-Yu (San Diego, CA), Rizzo; John (Oceanside, CA)
Assignee:	Covx Technologies Ireland Limited (Dublin, IE)
Application Number:	11/368,338
Patent Claims:	1. A compound having the formula: ##STR00274## or a pharmaceutically acceptable salt thereof. 2. A compound having the formula: ##STR00275## or a pharmaceutically acceptable salt thereof. 3. The compound of claim 1, wherein said aldolase antibody is h38c2 lgG1. 4. The compound of claim 1, wherein said aldolase antibody comprises a light chain comprising the amino acid sequence set forth in SEQ ID NO:40 and a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:41. 5. The compound of claim 2, wherein said aldolase antibody is h38c2 lgG1. 6. The compound of claim 2, wherein said aldolase antibody comprises a light chain comprising the amino acid sequence set forth in SEQ ID NO:40 and a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:41. 7. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1. 8. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 2. 9. The pharmaceutical composition of claim 7, further comprising a therapeutically effective amount of one or more chemotherapeutic agents. 10. The pharmaceutical composition of claim 9, wherein the one or more chemotherapeutic agents are selected from the group consisting of 5-flurouracil, irinotecan, oxaliplatin, bevacizumab, and cetuximab. 11. The pharmaceutical composition of claim 8, further comprising a therapeutically effective amount of one or more chemotherapeutic agents. 12. The pharmaceutical composition of claim 11, wherein the one or more chemotherapeutic agents are selected from the group consisting of 5-flurouracil, irinotecan, oxaliplatin, bevacizumab, and cetuximab.

Details for Patent 7,521,425

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004	⤷ Try a Trial	2025-03-03
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007	⤷ Try a Trial	2025-03-03
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004	⤷ Try a Trial	2025-03-03
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.